Pfizer management looks to show turnaround as Starboard looms
Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to demonstrate concrete re...
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
The company's problems are no longer deniable.
Pfizer's Activist Battle Might Fizzle---but Its Stock Probably Won't
The pharmaceutical company's stock is relatively cheap, representing an opportunity for patient value investors.
Final Trades: Pfizer, S&P Aerospace and Defense, and Live Nation
Today's Final Trades from the Investment Committee.
Gear Up for Pfizer (PFE) Q3 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte...
Starboard Slams Pfizer for R&D Inefficiencies, Overpaid Acquisitions
Starboard calls out PFE's board of directors to take action against the latter's management for not earning sustainable revenue returns on R&D and M&A.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note
Pfizer (PFE) reachead $28.93 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Pfizer: Activists Clouding A Promising Picture
Pfizer's deep valuation and large dividend yield make it an attractive investment, despite potential distractions from activist investors. The focus should remain on existing cost realignment plans...
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutic...
Tim Buckley Elected to Pfizer's Board of Directors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensiv...
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inc...
Related Companies